Modern Wealth Management LLC Boosts Stake in Becton, Dickinson and Company $BDX

Modern Wealth Management LLC boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 44.4% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,321 shares of the medical instruments supplier’s stock after acquiring an additional 406 shares during the quarter. Modern Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $303,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Saudi Central Bank purchased a new stake in Becton, Dickinson and Company during the first quarter valued at $26,000. Smallwood Wealth Investment Management LLC purchased a new stake in Becton, Dickinson and Company during the first quarter valued at $27,000. Alpine Bank Wealth Management purchased a new stake in Becton, Dickinson and Company during the first quarter valued at $29,000. REAP Financial Group LLC increased its position in Becton, Dickinson and Company by 75.3% during the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 55 shares during the last quarter. Finally, Cornerstone Planning Group LLC increased its position in Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 99 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.5%

Shares of BDX stock opened at $185.90 on Tuesday. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The stock’s 50 day simple moving average is $186.72 and its two-hundred day simple moving average is $190.98. The company has a market cap of $53.29 billion, a PE ratio of 33.44, a price-to-earnings-growth ratio of 1.51 and a beta of 0.27.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. During the same period in the prior year, the business posted $3.50 earnings per share. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is 74.82%.

Insider Activity at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 2,965 shares of company stock worth $551,536. Company insiders own 0.36% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on BDX shares. Citigroup cut Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and reduced their price objective for the company from $217.00 to $185.00 in a research report on Thursday, May 22nd. Wall Street Zen upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Morgan Stanley upped their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Wells Fargo & Company upped their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research report on Friday, August 8th. Finally, Barclays reduced their price target on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating for the company in a research report on Tuesday, June 3rd. Four analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $211.44.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.